Case Report: Personalized diagnosis and treatment strategies for three cases of cancer of unknown primary based on molecular testing techniques.

Front Oncol · 2025 · PMC11985444 · PMID 40224175

Europe PMC DOI

hedged sentence

0.0980

closest p · 2.0× alpha

0.0980

boldest claim

The sentences

showed a trendP = 0.098so close (0.05 < p ≤ 0.1)

6.6 months, HR = 0.68, 95% CI: 0.49–0.93, P = 0.017), and showed a trend toward longer OS (28.2 months vs. 19.0 months, HR = 0.74, 95% CI: 0.52–1.06, P = 0.098), suggesting a potential therapeutic advantage of molecularly guided treatment in CUP patients.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.